Bioequivalence and Pharmacokinetic Evaluation of Ethambutol 400 Mg Film-Coated Tablet
13 بار بازدید -
4 هفته پیش
-
Bioequivalence and Pharmacokinetic Evaluation of
Bioequivalence and Pharmacokinetic Evaluation of Ethambutol 400 Mg Film-Coated Tablet: A Single-Dose, Open-Label, Randomized, Two-Way Crossover Design Study
Priyanto1,2, Wahyono BH1, Widiastuti E1, Susilo MJ1, Yunica NT1, Pudjiati DJ3, and Reflinda Y3, 1Equitrust Lab, Jakarta, Indonesia, 2University of Muhammadiyah Prof. Dr. HAMKA, Indonesia, 3PT Kimia Farma tbk, Indonesia
Abstract
The objective of this study was to determine the bioequivalence of Ethambutol 400 mg Film-Coated Tablet produced by PT Kimia Farma Tbk compared to the WHOrecommended comparator product, Myambutol 400 mg Film-Coated Tablet produced by Pantheon Inc, Ontario, Canada for STI Pharma LLC, in healthy subjects. The study design used was a randomised two-way crossover design, single dose, open label, under fasting conditions. The number of subjects who completed the study was 29 of 32. Blood samples were collected 18 times. Ethambutol concentrations were determined by LCMS/MS method. Bioequivalence was determined by value of 90% confidence interval (CI) with α = 5.00% within the range of 80.00–125.00% for AUC and Cmax. The results of the statistical analysis for the bioequivalence study comparing the test drug to the comparator drug showed a geometric mean ratio (90% CI) of 103.67% (97.23-110.52%) for the area under the concentration-time curve (AUC0-t) and 91.53% (84.80-98.79%) for the maximum concentration (Cmax). Based on the result, the test drug is bioequivalent to the comparator drug.
Keywords
Ethambutol, AUC, Bioequivalence, Comparator, and Crossover
Full Text : https://ijcionline.com/paper/13/13424...
Volume URL : https://airccse.org/journal/IJBB/curr...
#comparator #crossover #biology #biotechnology #bioscience #bioinformatics
Priyanto1,2, Wahyono BH1, Widiastuti E1, Susilo MJ1, Yunica NT1, Pudjiati DJ3, and Reflinda Y3, 1Equitrust Lab, Jakarta, Indonesia, 2University of Muhammadiyah Prof. Dr. HAMKA, Indonesia, 3PT Kimia Farma tbk, Indonesia
Abstract
The objective of this study was to determine the bioequivalence of Ethambutol 400 mg Film-Coated Tablet produced by PT Kimia Farma Tbk compared to the WHOrecommended comparator product, Myambutol 400 mg Film-Coated Tablet produced by Pantheon Inc, Ontario, Canada for STI Pharma LLC, in healthy subjects. The study design used was a randomised two-way crossover design, single dose, open label, under fasting conditions. The number of subjects who completed the study was 29 of 32. Blood samples were collected 18 times. Ethambutol concentrations were determined by LCMS/MS method. Bioequivalence was determined by value of 90% confidence interval (CI) with α = 5.00% within the range of 80.00–125.00% for AUC and Cmax. The results of the statistical analysis for the bioequivalence study comparing the test drug to the comparator drug showed a geometric mean ratio (90% CI) of 103.67% (97.23-110.52%) for the area under the concentration-time curve (AUC0-t) and 91.53% (84.80-98.79%) for the maximum concentration (Cmax). Based on the result, the test drug is bioequivalent to the comparator drug.
Keywords
Ethambutol, AUC, Bioequivalence, Comparator, and Crossover
Full Text : https://ijcionline.com/paper/13/13424...
Volume URL : https://airccse.org/journal/IJBB/curr...
#comparator #crossover #biology #biotechnology #bioscience #bioinformatics
4 هفته پیش
در تاریخ 1403/05/30 منتشر شده
است.
13
بـار بازدید شده